HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

HPTN 084 PROTOCOL TEAM MEETING

Friday, September 29, 2023, 1:30pm – 5:00pm SAST
Grand Ballroom

Agenda:

- Welcome
- Publications
  - Overall Update
  - Product Choice Presentation
- V5.0 training
  - General Orientation to the V5.0
  - 2 Additional Injections (ONLY if Needed)
  - Updated CAB LA Risk Language
  - Clarified Data to be Collected for non4d Pregnant Women
- Pregnancy Refresher Training
  - Non-4d Pregnant PPTs and Infant Data Collection
  - 4d PPTs and Infant Data Collection
- v5.0 Scenarios
- ViiV Rollover Protocol Discussion
- Full Meeting Close Out

Remaining Time
Closed Meeting for SDMC and LC Discussions